|
|
Profile
|
Delegates :
Norio Hamamatsu, Ph.D. |
|
Incorporated :
April 7 , 2021 |
Paid in Capital :
215 Million yen |
Employees :
25 人 |
Address :
Aoba-ku Aramaki Azaaoba6-6-40 T-Biz, Sendai-si MIYAGI
〒980-0845
|
TEL/FAX :
/ |
URL：
https://www.revolka.com/en/ |
Attachment :
|
Mission/Background :
RevolKa is a biotechnology company, a core technology platform of which is an AI-assisted protein engineering technology: aiProtein(R). RevolKa is developing innovative mRNA therapeutics for rare diseases. aiProtein(R)-designed metabolic enzymes, called “Gain-of-Function enzymes” are delivered as mRNA to address patients’ unmet needs. RevolKa is also providing pharmaceutical and chemical companies with aiProtein(R) platform to create unprecedent proteins. The name "RevolKa" is derived from the Latin word for evolution, "evolutio” and the Ainu (an indigenous Japanese people) word for raise, “reska”. |
|
Technology & Business
|
aiProtein(R) is RevolKa’s innovative Machine Learning-driven protein engineering platform. It enables tailored AI-based protein engineering by building custom AI models using experimental data specifically collected from proteins of interest. Remarkably, aiProtein(R) requires only ~100 experimental data to train its AI engines. Moreover, aiProtein(R) supports multi-property optimization, such as activity, yield, stability, solubility and so on, at high success rates. This technology is a powerful and cost-effective solution for creating novel and highly functional proteins suitable for pharmaceutical and industrial applications.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
aiProtein(R) https://www.revolka.com/en.html
|
Launched
|
Customized AI models for proteins of interest to create innovative protein variants
|
Expanding collaboration opportunities with pharma, biotech and chemical companies
|
RevoAb(TM) https://revoab.revolka.com/en/
|
Launched
|
Online antibody engineering service, Customized AI models for antibody to generate variant sequences
|
Expanding business opportunity to global customers
|
Drug discovery
|
Discovery
|
Discovering aiProtein(R)-engineered high-performance enzymes and develop them as mRNA therapeutics.
|
Lead discovery Preclinical study
|
|
|
|
|
|
|
|
|
|
Highlights
|
In July 2025, RevolKa completed Series A extension funding to accelerate its drug discovery projects. Total funding reached 1 billion JPY. Partnership business has been rapidly expanding and initiated 15 projects since 2024. aiProtein(R) Antibody Engineering service is globally provided in collaboration with FUJIFILM Wako Chemicals (https://labchem-wako.fujifilm.com/us/category/95358.html).
|
|
Hot news
|
RevolKa was selected as one of 100 Japan's most prominent startups and venture companies for 2025, across all sectors - and one of 12 recognized in the healthcare/biotech sector - by a Japan's leading business magazine, TOYO Keizai.
|
|
Alliance strategy
|
RevolKa is looking for partnership opportunities of research collaboration to co-create cutting edge proteins by aiProtein(R). RevolKa also looks for potential partners for licensing its drug candidate assets. Furthermore, RevolKa looks for opportunities of academic collaboration of early therapeutic antibody discovery.
|
|
|